Preview complete
The prescreener preview is complete. You may now close the preview.
Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers with HIV
Recruiting
18-99 years
All
Phase
3
244 participants needed
1 Location
Brief description of study
The research
study is being conducted to examine the effects of personalized smoking
cessation medication treatment in order to help people with HIV/AIDS to quit
smoking. During the study, participants will take either varenicline (brand
name Chantix®) or use the nicotine patch, and they will receive smoking
cessation therapy with either standard smoking cessation medication adherence
advice or Managed Problem Solving intervention (MAPS).
If you agree to
join the study, you will be asked to complete the following research
procedures:
·
Attend
3 in person sessions (including this one) and complete 5 phone sessions.
·
Take
the study medication (either varenicline or nicotine patch) for up to 12 weeks.
·
Complete
up to 5 smoking cessation therapy sessions.
·
Provide
biological samples and physiological assessments.
·
Complete
brief psychiatric assessments and a routine medical history.
Your individual participation will last for about
7 months. By participating in this research study, you will have the
opportunity to participate in a smoking cessation program, which includes
counseling and varenicline and/or nicotine patch, at no cost.
If you are interested please click the following link to see if you are eligible:
PENN HTO Recruitment Survey
Detailed description of study
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Smoking,HIV
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 834345
Pre-Screener
